KRAS and cancer: Intriguingly, the combination of BI-2536 and fasudil at low doses led to a more robust reduction of cell viability than either single agent alone in KRAS-mutant, but not wild-type, cancer cells (Fig. 2b; Supplementary Fig. 2a).